ClinicalTrials.gg
RecruitingNCT06002659CARMA-01Updated Nov 10, 2026

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

A Phase 1/2 interventional study of CAR20(NAP)-T and Cyclophosphamide in B-cell Lymphoma, sponsored by Uppsala University. Recruiting at 2 sites in Sweden. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Uppsala University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 10, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Lymphoma, B-Cell with a site in Sweden — 4 open to participants now, 8 under way, 2 of them phase 3. Lymphoma, B-Cell · Sweden.

Planned enrollment
14th of 17
18 · median 270
Started
2024
with 2 others
Phase 1/2
5 of 17
1 open now
Registered
15th of 17
by date
Lead sponsor
3 of 17
Uppsala University

Among the 17 studies in Lymphoma, B-Cell with a site in Sweden, this one is the 14th largest by planned enrollment, is one of 3 that started in 2024, is one of 5 in phase 1/2, and was the 15th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

4 of the 17 studies in Lymphoma, B-Cell with a site in Sweden are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, B-Cell with a site in Sweden, or all of them as a file.
02

Study summary

The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.

Read the detailed description

A cancer patient's T cells can be isolated and engineered to express a chimeric antigen receptor (CAR), which re-directs the T cells to recognize and kill tumor cells expressing that particular antigen. CD19-targeted CAR-T cell therapy has shown good effects for B cell malignancies, even cure, in otherwise therapy refractory patients.

Antigen escape, i.e., the downregulation of the antigen targeted by the CAR due to the selective pressure caused by the CAR-T cell therapy is a challenge. For patients treated with CD19 CAR-T cell therapy, about 30% of the patients are resistant to treatment and about 20% of patients relapse after an initial response.

CAR20(NAP)-T cells target CD20 and upon target recognition secrete a bacterial-derived pluripotent immune-stimulating factor named NAP (Helicobacter pylori Neutrophil-activating protein). Secretion of NAP in the tumor microenvironment can induce an endogenous bystander immune response, that counteracts antigen escape and thereby improves the therapeutic outcome.

CAR20(NAP)-T is an investigational agent not yet approved by authorities.

Design:

The study is designed as 3+3 dose escalation phase I, and a dose expansion Phase IIa. The safety, tolerability, PK/PD, and efficacy will be evaluated.Dose escalation is to be based on the incidence of dose-limiting toxicity (DLTs). The investigator or sub-investigator will decide if the AE is related to IMP-treatment on a case-by-case basis depending on the character of the DLT symptoms. Investigator or sub-investigator has a possibility to classify various toxicity observed in patient as DLT.The Recommended phase II dose (RP2D) is decided based on safety, PK/PD data as well as preliminary clinical activity data from the Phase I dose escalation. After setting the RP2D, additional patients will be treated at RP2D to make sure at least 6 patients will be treated at RP2D dose level already at the phase I part.

Protocol treatment:

The enrolled patient will undergo a leukapheresis procedure to harvest enough T cells for IMP production. During CAR20(NAP)-T manufacturing, the patient may receive bridging therapy to control tumor burden. All patients will receive pre-conditioning chemotherapy (cyclophosphamide and fludarabine) followed by one dose of CAR20(NAP)-T cell infusion intravenously. The patient will then be followed by doctor/study nurse for evaluation of the health status and side effects. At follow-up visits, blood samples will be obtained and CT imaging will be performed. Patient will actively participate in the study for about 24 months when the final follow-up visit will be scheduled.

03

Conditions studied

  • B-cell Lymphoma

Browse trials for

Keywords

  • CAR T cell
  • B cell lymphoma
  • CD20
  • HP-NAP
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed .
  • CD20+ large B-cell lymphoma (DLBCL, NOS or high-grade malignant B-cell lymphoma), mantle cell lymphoma or indolent lymphoma.
  • The patient should have been treated with at least one and have no curative treatment option, assessed by the Investigator and documented in the source data prior to enrolment, specifically:

    1. Relapsed or refractory CD20+ B-cell lymphoma that are not suitable to receive clinically approved CD19-directed CAR T cell treatment
    2. Relapsed or refractory CD20+ B-cell lymphoma who are considered CD19 neg-ative
    3. Relapsed or refractory B-cell lymphoma who relapse after CD19-directed CAR T cell treatment
    4. Not suitable for stem cell transplant
    5. Relapsed after allogeneic transplantation
  • In phase I age >18 years, in phase II all ages.
  • per Lugano classification.
  • Performance status 0-2.
  • Bone marrow function, if impairment is not caused by lymphoma infiltration, as evidenced by:

    1. (ANC) ≥ 1x109/L
    2. ≥ 50x 109/L
    3. Absolute lymphocyte count ≥ 0.1x109/L
  • Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

    1. (Cockcroft Gault) ≥ 30 mL/min
    2. Serum /Aspartate aminotransferase (ALT/AST) ≤ 2.5 (ULN) and S- \<1.5x UNL
    3. Cardiac ≥ 40%
  • Functional venous access for administration of IMP.
  • Fertile individuals must consent to use during participation in the trial.

Exclusion Criteria:

  • Other CD20-positive lymphomas e.g Burkitt lymphoma, primary CNS lymphoma, plasmablastic lymphoma or CLL transformed to DLBCL/HGBL (Richter transformation)
  • Any significant medical or psychiatric illness that would prevent the subject from giving informed consent or from following the study procedures.
  • Known (HIV) infection.
  • Impending organ-compromising disease.
  • Rapidly progressing disease
  • Active and/or severe infection (e.g., tuberculosis, sepsis and opportunistic infections, active virus (HBV) or active virus (HCV) infection.
  • Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the subject to tolerate the treatment.
  • Treatment with an product within 30 days prior to enrolment
  • Potential sign of reaction to tocilizumab or any of the agents used in this study
  • Systemic treatment (>10mg/day) \<5 days prior to IMP treatment or \<7 days prior leukapheresis.
  • Pregnancy
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Treatment

    CAR20(NAP)-T treatment

    Biological: CAR20(NAP)-T · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • BiologicalCAR20(NAP)-T

    Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP

    Also known as: ELC-301

  • pre-conditioning chemotherapy

  • pre-conditioning chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity

    The incidence of dose limiting toxicity (DLT). Number of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs)

    Time frame: First infusion up to 30 days

  2. Adverse events

    The nature, frequency, severity, and tolerability of adverse events (AEs) including clinically significant laboratory data, and their relation to dosage.

    Time frame: 24 months

  3. Pharmacodynamic (PD) and pharmacokinetic (PK)

    PD is assessed by determine circulating B cell level; PK is assessed by determine circulating CAR20(NAP)-T cells.

    Time frame: Either 24 month or 15 years during long-term follow up if clinically indicated

Secondary outcomes

  1. Objective response rate [ORR]

    ORR is defined as the incidence of a complete response or a partial response by the revised Lugano classification as determined by the study investigators. All patients that do not meet the criteria for an objective response by the analysis cutoff date will be considered non-responders.

    Time frame: 24 months

  2. Progression free survival [PFS]

    PFS is defined as the time from the IMP treatment date to the date of disease progression per the revised Lugano classification or death from any cause.

    Time frame: 24 months

  3. Best Objective Response

    the incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as best response to treatment.

    Time frame: 24 months

  4. Duration of Response (DOR)

    DOR is defined as the date of their first objective response (which is subsequently confirmed) to disease progression per the revised Lugano classification or death regardless of cause. Patients not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing.

    Time frame: 24 months

  5. Overall Survival (OS)

    defined as the time from IMP treatment to the date of death. Patients alive by the analysis data cutoff date will be censored at their last contact date. The overall survival rate will be reported at different cut-off time points.

    Time frame: either 24 months or 15 years during long-term follow up if clinically indicated

Other outcomes

  1. Anti-NAP response

    Determine anti-NAP immune response

    Time frame: either 24 months or 15 years during long-term follow up if clinically indicated

  2. Bystander immunity activation

    Assess induced tumor specific endogenous T-cell immune response

    Time frame: either 24 months or 15 years during long-term follow up if clinically indicated

07

Study locations

2 of 2 sites recruiting
  • Karolinska University Hospital
    Stockholm, Sweden
    Recruiting
    • Stephan Mielke · Contact
    • Stephan Mielke, MD, PhD · Principal investigator
  • Uppsala University Hospital
    Uppsala, Sweden
    Recruiting
    • Gunilla Enblad · Contact
    • Gunilla Enblad, MD/PhD · Principal investigator
08

References and documents

Publications

  • Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng. 2022 Jul;6(7):830-841. doi: 10.1038/s41551-022-00875-5. Epub 2022 Apr 4. PubMed 35379957 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.

Of 52 non-industry phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 82. This study's planned 55 months is below that.

Counting every sponsor, half of 94 studies reached it within 71 months; a quarter within 55 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2027 → Dec 2028 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Aug 21, 2023
StartActual
May 1, 2024
Primary completionEst.
Dec 30, 2028was Dec 2027
CompletionEst.
Dec 30, 2028was Dec 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Karolinska University Hospital is now Recruiting
Nov 10, 2026
Primary completion
Dec 30, 2027→Dec 30, 2028
Nov 10, 2026
Study completion
Dec 30, 2027→Dec 30, 2028
Nov 10, 2026
Eligibility
12 criteria edited, 2 added
What changed in the criteria
  • EditedRelapsed or refractory CD20+ diffuse large B-cell lymphoma (DLBCL, NOS or high-grade malignant B-cell lymphoma), mantle cell lymphoma or indolent lymphoma.
  • EditedThe patient should have been treated with at least two linesone line of therapy and have no curative treatment option, assessed by the Investigator and documented in the source data prior to enrolment, specifically:
  • EditedRelapsed or refractory CD20+ B-cell lymphoma that are not eligiblesuitable to receive clinically approved CD19-directed CAR T cell treatment.
  • EditedRelapsed or refractory CD20+ B-cell lymphoma who are considered CD19 negative.neg-ative
  • EditedRelapsed or refractory B-cell lymphoma who relapse after CD19-directed CAR T cell treatment.
  • AddedNot suitable for autologous stem cell transplant
  • AddedRelapsed after allogeneic transplantation
  • EditedAdequate boneBone marrow function, if impairment is not caused by lymphoma infiltration, as evidenced by:
  • EditedAbsolute neutrophil count (ANC) ≥ 1x10\^9/l1x109/L
  • EditedPlatelet ≥ 50x 10\^9109/lL
  • EditedAbsolute lymphocyte count ≥ 0,1x10\^9.1x109/L
  • EditedFunctional venous access for administration of IMP.
  • EditedOther CD20-positive lymphomas ie.eg Burkitt lymphoma, primary CNS lymphoma, plasmablastic lymphoma or CLL transformed to DLBCL/HGBL (Richter transformation)
  • EditedOther serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the subject to performtolerate the treatment.
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Karolinska University Hospital · Stockholm, SwedenContact added (no phone or email listed)Contact added (no phone or email listed)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Karolinska University Hospital is now Recruiting
    Primary completion Dec 30, 2027→Dec 30, 2028
    Study completion Dec 30, 2027→Dec 30, 2028
    Eligibility 12 criteria edited, 2 added
    What changed in the criteria
    • EditedRelapsed or refractory CD20+ diffuse large B-cell lymphoma (DLBCL, NOS or high-grade malignant B-cell lymphoma), mantle cell lymphoma or indolent lymphoma.
    • EditedThe patient should have been treated with at least two linesone line of therapy and have no curative treatment option, assessed by the Investigator and documented in the source data prior to enrolment, specifically:
    • EditedRelapsed or refractory CD20+ B-cell lymphoma that are not eligiblesuitable to receive clinically approved CD19-directed CAR T cell treatment.
    • EditedRelapsed or refractory CD20+ B-cell lymphoma who are considered CD19 negative.neg-ative
    • EditedRelapsed or refractory B-cell lymphoma who relapse after CD19-directed CAR T cell treatment.
    • AddedNot suitable for autologous stem cell transplant
    • AddedRelapsed after allogeneic transplantation
    • EditedAdequate boneBone marrow function, if impairment is not caused by lymphoma infiltration, as evidenced by:
    • EditedAbsolute neutrophil count (ANC) ≥ 1x10\^9/l1x109/L
    • EditedPlatelet ≥ 50x 10\^9109/lL
    • EditedAbsolute lymphocyte count ≥ 0,1x10\^9.1x109/L
    • EditedFunctional venous access for administration of IMP.
    • EditedOther CD20-positive lymphomas ie.eg Burkitt lymphoma, primary CNS lymphoma, plasmablastic lymphoma or CLL transformed to DLBCL/HGBL (Richter transformation)
    • EditedOther serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the subject to performtolerate the treatment.
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Karolinska University Hospital · Stockholm, SwedenContact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06002659
Lead sponsor
Uppsala University
Collaborators
Elicera Therapeutics, Uppsala University Hospital, Karolinska University Hospital
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
May 1, 2024
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Gunilla Enblad, MD/PhD
Contact
gunilla.enblad@igp.uu.se
+46186110000
Di Yu, PhD
Contact
di.yu@igp.uu.se
+46707204196
Di Yu, PhD
study director · Uppsala University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion